SPI Generative AI: OpenAI and the Opportunities in Pharma

Drug discovery continues to be among the use cases for generative AI which is garnering the most traction. Several stories have recently typified this utilisation, with AI-powered drug discovery firm Xaira launching with $1bn in capital, while Moderna, a vendor largely focused on mRNA vaccines, pharmaceutical company Sanofi and drug developer Formation Bio have partnered with OpenAI.

The Signify View

Drug discovery is an area ripe for an AI transformation. While the revenue potential for successful treatments is immense, getting to the stage where such revenues can be recognised is long, arduous and fraught with failure.